ANTARES PHARMA INC (ATRS) Fundamental Analysis & Valuation

NASDAQ:ATRS • US0366421065

Current stock price

5.59
0 (0%)
At close:
5.59
0 (0%)
After Hours:

This ATRS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ATRS Profitability Analysis

1.1 Basic Checks

  • In the past year ATRS was profitable.
ATRS Yearly Net Income VS EBIT VS OCF VS FCFATRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M 40M

1.2 Ratios

Industry RankSector Rank
ROA 17.97%
ROE 26.33%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATRS Yearly ROA, ROE, ROICATRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 20 -20 40 -40

1.3 Margins

Industry RankSector Rank
OM 14.87%
PM (TTM) 25.15%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATRS Yearly Profit, Operating, Gross MarginsATRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 20 -20 40 -40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. ATRS Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, ATRS has more shares outstanding
  • ATRS has a better debt/assets ratio than last year.
ATRS Yearly Shares OutstandingATRS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 50M 100M 150M
ATRS Yearly Total Debt VS Total AssetsATRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M 250M

2.2 Solvency

  • ATRS has an Altman-Z score of 8.15. This indicates that ATRS is financially healthy and has little risk of bankruptcy at the moment.
  • ATRS has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z 8.15
ROIC/WACCN/A
WACCN/A
ATRS Yearly LT Debt VS Equity VS FCFATRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 50M 100M 150M

2.3 Liquidity

  • ATRS has a Current Ratio of 2.96. This indicates that ATRS is financially healthy and has no problem in meeting its short term obligations.
  • ATRS has a Quick Ratio of 2.76. This indicates that ATRS is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 2.96
Quick Ratio 2.76
ATRS Yearly Current Assets VS Current LiabilitesATRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. ATRS Growth Analysis

3.1 Past

  • ATRS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 350.00%, which is quite impressive.
  • ATRS shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.99%.
  • ATRS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.65% yearly.
EPS 1Y (TTM)350%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%533.33%
Revenue 1Y (TTM)22.99%
Revenue growth 3Y42.49%
Revenue growth 5Y28.65%
Sales Q2Q%10.42%

3.2 Future

  • ATRS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.76% yearly.
  • Based on estimates for the next years, ATRS will show a quite strong growth in Revenue. The Revenue will grow by 17.75% on average per year.
EPS Next Y-69.78%
EPS Next 2Y-9.18%
EPS Next 3Y8.49%
EPS Next 5Y41.76%
Revenue Next Year15.42%
Revenue Next 2Y18.38%
Revenue Next 3Y17.73%
Revenue Next 5Y17.75%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ATRS Yearly Revenue VS EstimatesATRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M 400M
ATRS Yearly EPS VS EstimatesATRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

1

4. ATRS Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 20.70, ATRS is valued on the expensive side.
  • The average S&P500 Price/Earnings ratio is at 26.64. ATRS is valued slightly cheaper when compared to this.
  • With a Price/Forward Earnings ratio of 68.50, ATRS can be considered very expensive at the moment.
  • When comparing the Price/Forward Earnings ratio of ATRS to the average of the S&P500 Index (21.36), we can say ATRS is valued expensively.
Industry RankSector Rank
PE 20.7
Fwd PE 68.5
ATRS Price Earnings VS Forward Price EarningsATRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 29.05
ATRS Per share dataATRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.18%
EPS Next 3Y8.49%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ATRS Dividend Analysis

5.1 Amount

  • No dividends for ATRS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ATRS Fundamentals: All Metrics, Ratios and Statistics

ANTARES PHARMA INC

NASDAQ:ATRS (5/23/2022, 8:12:09 PM)

After market: 5.59 0 (0%)

5.59

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)05-10
Earnings (Next)08-03
Inst Owners0.26%
Inst Owner Change0%
Ins Owners6.83%
Ins Owner Change0%
Market Cap955.06M
Revenue(TTM)183.98M
Net Income(TTM)46.28M
Analysts73.33
Price Target6.07 (8.59%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 20.7
Fwd PE 68.5
P/S 5.19
P/FCF N/A
P/OCF N/A
P/B 5.43
P/tB N/A
EV/EBITDA 29.05
EPS(TTM)0.27
EY4.83%
EPS(NY)0.08
Fwd EY1.46%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.08
BVpS1.03
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA 17.97%
ROE 26.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 14.87%
PM (TTM) 25.15%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.96
Quick Ratio 2.76
Altman-Z 8.15
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)350%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%533.33%
EPS Next Y-69.78%
EPS Next 2Y-9.18%
EPS Next 3Y8.49%
EPS Next 5Y41.76%
Revenue 1Y (TTM)22.99%
Revenue growth 3Y42.49%
Revenue growth 5Y28.65%
Sales Q2Q%10.42%
Revenue Next Year15.42%
Revenue Next 2Y18.38%
Revenue Next 3Y17.73%
Revenue Next 5Y17.75%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

ANTARES PHARMA INC / ATRS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ANTARES PHARMA INC?

ChartMill assigns a fundamental rating of 6 / 10 to ATRS.


What is the valuation status for ATRS stock?

ChartMill assigns a valuation rating of 3 / 10 to ANTARES PHARMA INC (ATRS). This can be considered as Overvalued.


Can you provide the profitability details for ANTARES PHARMA INC?

ANTARES PHARMA INC (ATRS) has a profitability rating of 6 / 10.


Can you provide the financial health for ATRS stock?

The financial health rating of ANTARES PHARMA INC (ATRS) is 6 / 10.


Can you provide the expected EPS growth for ATRS stock?

The Earnings per Share (EPS) of ANTARES PHARMA INC (ATRS) is expected to decline by -69.78% in the next year.